Global Medical Device Podcast powered by greenligh

The FDA is actively shaping the regulatory landscape for Artificial Intelligence (AI) and Machine Learning (ML) in real time. As the agency expands its internal expertise through the Digital Health Center of Excellence, FDA reviewers are becoming highly sophisticated. The era of submitting vague algorithm descriptions is over, paving the way for a more level playing field that rewards companies executing documentation correctly. Navigating this evolving space requires a dual-front approach for global medical device companies. Manufacturers must balance the FDA's framework with the EU AI Act, which classifies AI medical devices as high-risk systems demanding rigorous conformity assessments and human oversight. Fortunately, a robust quality management system designed around proactive frameworks, such as the Predetermined Change Control Plan (PCCP), can bridge the gap between US and international expectations. For Quality Assurance and Regulatory Affairs (QA/RA) professionals, this shift represents an unprecedented career opportunity. The future belongs to those who combine regulatory fluency with AI literacy. Success in the MedTech industry will not belong solely to the most complex algorithm, but to the companies and professionals who build compliant, disciplined systems around their AI technologies. Key Timestamps00:19 – Introduction to the current state of FDA AI regulation and leadership transitions. 01:34 – The role of the FDA Digital Health Center of Excellence and shifting reviewer expectations. 02:08 – Navigating global regulations: Balancing the EU AI Act and EU MDR. 02:46 – The 5 guiding principles for AI/ML-based Software as a Medical Device (SaMD). 03:41 – Analyzing FDA warning letters: Why documentation takes precedence over algorithm performance. 04:19 – Bridging the language barrier between AI engineers and FDA reviewers in submissions. 05:27 – The future of QA/RA careers: The rising demand for AI-literate regulatory professionals. 06:21 – Actionable strategies to stay ahead: Implementing PCCPs early and training quality teams. 07:23 – Treating post-market surveillance for AI products as an evolving product lifecycle. Quotes"The companies getting in trouble aren't the ones with bad AI, they're the ones with incomplete quality systems." - Etienne Nichols"Your job in a regulatory submission is not to demonstrate that your AI is sophisticated. Your job is to demonstrate that it's safe and effective in its intended use." - Etienne NicholsTakeawaysBuild Your PCCP First: Develop your Predetermined Change Control Plan (PCCP) concurrently with or prior to algorithm development to ensure post-clearance modifications match your design process. Close the Team Knowledge Gap: Educate quality engineering teams on fundamental AI concepts like training data, validation datasets, and demographic representation before facing regulatory audits. Proactively Audit Your DHF: Review your existing Design History File (DHF) against current FDA AI guidance documents well ahead of submission deadlines to eliminate documentation gaps without timeline pressure. Evolve Post-Market Surveillance: Treat your AI post-market surveillance plan as a living product by implementing version control, clear ownership, and defined thresholds to detect algorithm drift. Achieve Dual Literacy for Career Growth: QA/RA professionals who master both regulatory frameworks and basic AI literacy will position themselves at the top of an uncrowded talent pool. ReferencesFDA, Health Canada, & UK MHRA Joint Statement (2022): The five joint guiding principles established for machine learning medical device development. FDA AI/ML Action Plan (2021) & PCCP Guidance (2023): Core foundational reading material for understanding regulatory expectations. International Medical Device Regulators Forum (IMDRF) Guidance: Global harmonized guidelines concerning AI/ML-based SaMD. EU AI Act: High-risk classification rules and conformity requirements affecting medical software in Europe. Connect with the Host: Follow Etienne Nichols on LinkedIn for more MedTech insights and discussion. MedTech 101 SectionOverfittingThink of overfitting like a student who memorizes the exact questions and answers on a practice exam instead of learning the underlying concepts. When they take the real test with slightly altered questions, they fail. In AI, overfitting happens when an algorithm learns the training data too perfectly, making it excellent at analyzing that specific dataset but unable to make accurate predictions on new patient data. Algorithm DriftImagine a GPS map app that was programmed perfectly five years ago. Over time, new roads are built, traffic patterns change, and old exits close. If the app is never updated, its navigation becomes less accurate. Algorithm drift occurs when an AI medical device becomes less effective over time because the real-world clinical environment or patient demographics shift away from the original data it was trained on. SponsorsThis episode is brought to you by Greenlight Guru. Navigating the fast-moving compliance landscape for AI-enabled medical devices requires software that keeps pace with innovation. Greenlight Guru offers comprehensive Quality Management System (QMS) and Electronic Data Capture (EDC) solutions designed specifically for MedTech. By streamlining your documentation, tracking design history, and capturing robust clinical data, Greenlight Guru helps you build the rigorous quality systems required to clear regulatory hurdles globally. Learn more at www.greenlight.guru. Feedback Call-to-ActionWe want to hear from you! What are your thoughts on the future of AI regulation? Are you implementing PCCPs in your current workflows? Send your thoughts, feedback, and topic suggestions to podcast@greenlight.guru. Etienne reads and responds to emails personally, and your ideas could shape our next episode!

The MedTech industry widely misread the FDA's recent warning letter to Purolea Cosmetics Lab as a direct crackdown on Artificial Intelligence (AI). Host Etienne Nichols challenges this narrative, explaining that viewing the event strictly through an AI lens causes medical device manufacturers to miss the actual compliance lesson. At its core, the Purolea situation is not a story of bad software, but rather a fundamental failure of process validation and quality system oversight. When stripped of its technical novelty, the regulatory citation reveals an inspector's nightmare: lack of microbiological testing, absent process validation, and a non-functional quality unit. The AI components were merely downstream symptoms of a quality vacuum. Purolea utilized AI agents to draft critical product specifications and master production records, blindly trusting the software without human oversight. When confronted, the company claimed the AI agent simply never informed them that process validation was a legal requirement. For medical device companies shifting from pharmaceutical regulations to the Quality Management System Regulation (QMSR), this episode serves as an urgent reminder of human accountability. The FDA did not write new regulations for this case; they applied foundational principles of human ownership to automated outputs. Whether content is drafted by a junior intern or a Large Language Model (LLM), a qualified human must own, review, and validate the output against defined specifications within a controlled, compliant architecture. Key Timestamps00:15 - The Purolea Cosmetics Lab warning letter and the media's misinterpretation of an FDA AI crackdown. 01:04 - The reality of the Purolea inspection: Pests, missing microbiological tests, and total quality vacuum. 01:42 - How Purolea used AI agents to draft production records and why blaming the algorithm failed. 02:18 - 21 CFR Part 211.22 and its medical device parallel (QMSR 820.20): Defining the Quality Control unit’s ultimate accountability. 03:11 - Treating AI as an internal consultant: The balance of sensitivity and specificity in automated tools. 04:00 - Can you validate an AI algorithm vs. inspecting outputs? Deterministic software vs. Machine Learning. 05:25 - The 3-Part Validation Data Framework: Training data, validation data (development set), and the holdout test data. 06:21 - When human-in-the-loop output verification works, and when 100% automated inspection fails. 07:22 - Deep dive into Computer Software Assurance (CSA) guidance and risk-proportionate validation rigor. 08:16 - Essential regulatory standards and guidance documents list for MedTech AI developers. 09:25 - The 2010s Paper vs. eQMS debate compared to modern unstructured AI chat windows. 10:35 - Five concrete questions to assess if your quality system is ready for an FDA AI inspection. Quotes"If you use AI as an aid in document creation, you must review the AI generated documents to ensure that they were accurate and actually compliant... The person who signed off on them is responsible. This is nothing new." - Etienne Nichols"A perfectly engineered AI agent drafting into a quality vacuum is going to produce the same results as a sloppy one." - Etienne NicholsTakeawaysHuman-in-the-Loop Ownership: Automated tools must be treated like junior interns or external consultants. Every document, specification, or SOP drafted by an LLM requires rigorous, qualified human review and physical signature sign-off before entering a controlled QMS. Strict Split for ML Data Sets: For true machine learning algorithmic validation, companies must strictly partition data into Training, Validation, and Holdout Test data. Merging or leaking data between validation and training sets entirely compromises the regulatory integrity of the submission. Validation Rigor Must Match Risk Profile: Under Computer Software Assurance (CSA) principles and ISO 14971, validation intensity must be proportionate to risk. Low-risk form-populators do not require the same exhaustive testing protocols as automated diagnostic algorithms driving real-time clinical decisions. Chat History is Not an Audit Trail: Pasting AI outputs from an uncontrolled chat window into unmanaged text editors violates electronic record standards. AI-assisted documentation must reside within an infrastructure that maintains version control and clear change histories. ReferencesFDA Guidance (2002): General Principles of Software Validation — The bedrock document for baseline software expectations in medical tech. FDA Guidance Update: Computer Software Assurance (CSA) for Production and Quality System Software — The framework shifting focus from excessive paperwork to risk-based testing assurance. International Standard ISO 13485: Medical devices — Quality management systems — The global standard now tied directly into US compliance via the QMSR transition. International Standard ISO 14971: Medical devices — Application of risk management to medical devices — The foundational blueprint for mapping out software hazard severity. Etienne Nichols' LinkedIn: Connect with the host directly for full access to the original Purolea blog post breakdown and further MedTech compliance discussions. MedTech 101 SectionAlgorithmic Data Splitting: The "Final Exam" AnalogyTo understand how machine learning models are validated without testing every infinite possibility, think of the process like preparing a medical student for a board certification exam: Training Data (The Textbook): This is the information the AI studies. It looks at thousands of examples to learn what a pattern looks like. Validation Data (The Practice Quizzes): This data is used during development to fine-tune the model, fix minor errors, and adjust its parameters. The student takes these quizzes to see where they need to study harder. Test Data (The Final Exam): This is a completely hidden, clean set of data that the model has never seen before. True validation only happens here. If you test an AI on data it already saw during its training phase, it hasn't proven it can think—it has just proven it can memorize the answer key. SponsorsThis episode is brought to you by Greenlight Guru. Navigating the intersection of automated engineering tools and strict regulatory expectations requires an unshakeable quality architecture. Greenlight Guru provides purpose-built Medical Device QMS (Quality Management System) and EDC (Electronic Data Capture) solutions designed to help MedTech companies maintain ironclad human oversight, compliant audit trails, and risk-proportionate validation pathways. Ensure your innovative tools enter a structured, defensive quality environment rather than a regulatory vacuum. Feedback Call-to-ActionDid this episode change how you view your team's use of automated tools? Do you have a different take on how the QMSR handles machine learning validation? We want to hear from you. We read and personally respond to every listener message. Send your feedback, constructive pushback, or future episode topic suggestions directly to our production desk at podcast@greenlight.guru.

The medical device industry is undergoing a paradigm shift as Artificial Intelligence (AI) and Machine Learning (ML) transition from novelties into heavily regulated realities. The turning point arrived when the FDA integrated its own internal AI tool, Elsa, into its scientific review and inspection targeting processes. With regulators actively leveraging the technology, MedTech companies can no longer treat AI as a buzzword; it demands a deep understanding of concrete regulatory frameworks and actual engineering rules. To properly understand this evolution, the traditional internet analogy must be cast aside in favor of a more accurate comparison: electricity. Just as the adoption of electricity brought a wave of safety infrastructure, inspectors, and the National Electrical Code, AI is bringing an imminent mountain of new standards to the medical device landscape. Winning device companies will not be those that market themselves as "AI companies," but rather those whose devices simply perform better because of the technology and whose quality systems can explicitly prove that enhanced performance to regulators. Navigating this terrain requires mastering fundamental regulatory concepts, beginning with Software as a Medical Device (SaMD) pathways and the distinction between locked and adaptive algorithms. Because adaptive algorithms continuously change in the field, they present a unique regulatory challenge that requires a total product lifecycle approach. By utilizing a Predetermined Change Control Plan (PCCP) and integrating proactive post-market surveillance directly into the Quality Management System (QMS), manufacturers can successfully clear these checkpoints and avoid costly deficiency letters. Key Timestamps00:19 – The evolution of AI from an amusing novelty to industry fatigue. 00:54 – The turning point: The FDA's adoption of Elsa in its internal scientific review process. 01:34 – Moving past the hype: Focus on the actual rules of AI in MedTech. 01:54 – The Electricity Analogy: Shifting from candles to infrastructure and the National Electrical Code. 03:13 – The Electric Toaster lesson: Focus on a better product, not the technology powering it. 03:57 – Understanding Software as a Medical Device (SaMD) as a full regulatory pathway. 04:26 – Micro-timestamp: Defining Locked vs. Adaptive Algorithms and the core regulatory challenges of evolving data. 05:14 – The Total Product Lifecycle Approach: Viewing FDA clearance as a checkpoint, not a finish line. 05:40 – Breaking down the 2021 AI/ML Action Plan and its five core areas of focus. 06:17 – Deep dive into Predetermined Change Control Plans (PCCPs) and the Omnibus Act framework. 06:55 – Micro-timestamp: The three mandatory components of a successful PCCP submission. 07:54 – Evaluating the 2021 draft guidance on 510(k) considerations for AI/ML-based SaMD. 08:04 – Micro-timestamp: Data requirements (training, validation, testing) and managing demographic/clinical bias. 08:35 – Algorithm transparency: Balancing proprietary tech with reviewer clarity. 08:58 – Building QMS infrastructure for AI: Moving away from retrofitted legacy systems. 09:27 – Micro-timestamp: Applying Risk Management under ISO 14971 and AAMI TIR34971 to AI-specific failure modes. 10:14 – Proactive vs. Reactive Post-Market Surveillance: Tracking algorithm drift in the real world. 10:53 – Key takeaways and lessons learned from building an off-grid home electrical system. 11:59 – Teaser for next week: Common mistakes and patterns that trip up companies in AI submissions. Quotes"The device companies that are going to win aren't the ones making the biggest deal out of having AI. They're the ones whose devices actually work better because of it and whose quality systems can prove that to the FDA." - Etienne Nichols"With AI, clearance is more of a checkpoint. You're going to have multiple of these checkpoints along the way." - Etienne NicholsTakeawaysRegulatory & SubmissionsTreat the PCCP as an Operational Reality: A Predetermined Change Control Plan cannot be written at the last minute as a mere submission document. It must strictly reflect your active software development process, covering planned modifications, modification protocols, and detailed impact assessments. Ensure Data Demographics Match Intended Use: The FDA scrutinizes the clinical, geographical, and demographic composition of your training, validation, and testing data. Algorithms must perform consistently across subpopulations to prevent significant safety risks. Commit to Algorithm Transparency: While the FDA does not require your proprietary source code, you must explain the algorithm's functionality and failure modes clearly enough for a reviewer to confidently assess its safety and effectiveness. Quality Management Systems (QMS)Design Controls and AI Risk Mitigation: QMS architectures must be built from the ground up to handle AI-specific failure modes (such as false positives, false negatives, or subpopulation anomalies) using risk management standards like ISO 14971 and specialized guides like AAMI TIR34971. Transition to Proactive Post-Market Surveillance: Traditional, reactive complaint handling is insufficient for adaptive algorithms. Quality systems must incorporate continuous, active real-world monitoring to detect and rectify algorithm drift before it compromises patient safety. ReferencesFDA AI/ML Action Plan (2021): The foundation document outlining the agency's five-part focus on software modification, PCCPs, good machine learning practices, patient-centered transparency, and real-world monitoring. 510(k) Considerations for AI/ML-Based SaMD Draft Guidance: Critical guidance emphasizing data splitting protocols, demographic representation, and algorithm transparency. ISO 14971 & AAMI TIR34971: The essential consensus standard and technical information report mapping out the application of risk management principles specifically to machine learning and artificial intelligence. Etienne Nichols' LinkedIn Profile: Connect directly with host Etienne Nichols on LinkedIn to share feedback, ask questions, and discuss the latest trends in MedTech regulatory affairs. MedTech 101 SectionSoftware as a Medical Device (SaMD)SaMD is software designed to perform medical functions—such as diagnosing, treating, or monitoring diseases—without being part of physical medical device hardware. The Analogy: Think of a traditional medical device as a dedicated physical calculator sitting on a doctor's desk. SaMD is like a medical application downloaded onto a standard smartphone; the phone itself isn't the medical device, but the software running inside it is acting as one. Locked vs. Adaptive AlgorithmsA Locked Algorithm is an AI model that remains completely unchanged after it is cleared and deployed. It performs its function exactly the same way every time until the manufacturer manually pushes a controlled update. An Adaptive Algorithm is an AI model that continues to learn, retrain, and evolve on its own based on new real-world patient data after it is deployed. The Analogy: A locked algorithm is like a physical cookbook printed on paper; the recipes never change unless the publisher prints a second edition. An adaptive algorithm is like a living chef who tastes every dish they make, continuously altering the recipe over time based on feedback from the diners. Feedback Call-to-ActionWe want to hear from you. Did this episode change how you look at your company's AI pipeline? Do you have questions about implementing a PCCP or structuring your design controls for machine learning? We read every single message and love delivering personalized responses to our community. Send your thoughts, feedback, reviews, or topic suggestions for future episodes directly to our team at podcast@greenlight.guru. SponsorsThis episode of the Global Medical Device Podcast is brought to you by Greenlight Guru. Navigating the complex landscape of AI/ML regulations requires an airtight quality foundation. Greenlight Guru provides specialized Medical Device Success Platforms that unify your team’s efforts. By utilizing their dedicated QMS (Quality Management System) solutions, you can seamlessly build AI-specific design controls and map out risk management strategies under ISO 14971. Furthermore, their integrated EDC (Electronic Data Capture) solutions allow you to execute rigorous clinical data collection, helping you gather the high-quality, traceable real-world performance data required to monitor algorithm drift and satisfy total product lifecycle demands. Discover how to scale your AI enabled innovation safely by visiting www.greenlight.guru.

The transition from a cleared medical device to a commercialized product is one of the most perilous phases for a MedTech startup. While founders frequently anticipate the technical and regulatory hurdles of early-stage development, they often underestimate the "commercial valley of death." Success in the modern healthcare economy requires more than a functional prototype and clinical validation; it requires an exact blueprint to navigate the complex organizational structures of health systems, ambulatory surgery centers, and value analysis committees. A primary pitfall for early-stage innovators is the discrepancy between clinical data expectations and real-world market entry. Founders naturally possess an unwavering belief in their technology to secure funding, yet this can inadvertently lead to an overestimation of rapid adoption and an underestimation of institutional purchasing complexity. Mitigating this pressure requires integrating strategic commercial leadership early in the timeline—often months prior to receiving regulatory clearance—to properly align the market profile and build institutional momentum before the product officially launches. Choosing the right commercial framework depends heavily on the disruptive nature of the device itself. While traditional hiring mechanisms or independent distributors can be effective for incremental or transactional product categories, highly disruptive technologies and high-ticket capital equipment demand a deeper, more execution-focused partnership. Implementing a modern, fractional commercial model provides seed-stage companies with a capital-efficient method to engage veteran industry strategics, reassure investors, establish clear operational ROI for hospital administrators, and build a lasting culture of advocacy within clinical environments. Key Timestamps00:01 – Introduction to the Commercial Valley of Death: Etienne Nichols introduces guest Ryan O'Mahoney and redefines the "valley of death" as the treacherous phase spanning prototyping, global scaling, and institutional market adoption. 03:24 – The Underestimation vs. Overestimation Trap: Analysis of why clinical data optimism can lead to inflated forecasting and a failure to anticipate the procedural gauntlet of modern hospital purchasing. 04:51 – Optimal Timing for Commercial Integration: When founders should bring on commercial expertise, highlighting why a few months prior to FDA clearance is the ideal window to build momentum. 07:41 – Investor and Strategic Benefits: How early commercial positioning signals stability to venture capitalists, enhances company valuations, and opens doors for strategic corporate exits. 10:03 – Go-To-Market Frameworks Compared: A breakdown of traditional full-time hiring, utilizing independent consultants, and leveraging distribution networks, alongside the risks and benefits of each. 13:16 – The Rise of Modern Fractional Commercial Models: Exploring the hybrid approach as a capital-preserving mechanism designed for maximum impact on initial adoption. 15:06 – The Three Non-Negotiable Pillars of Adoption: Introduction of the foundational framework required to pass go: clinical superiority, technical clinician enhancement, and administrative return on investment. 18:59 – Escaping Perpetual Pilot Programs: Strategies to convert early clinical interest and hospital trials into concrete, multi-million dollar purchase orders. 22:30 – Navigating Value Analysis and Hospital Budgets: How to pivot the conversation from purely clinical superiority to operational and economic ROI for healthcare administration. 25:27 – Recruiting and Managing High-Intellect Commercial Teams: Building an organizational culture centered around purpose, passion, and retaining the founding team as an inspirational backbone. Quotes"They underestimate the complexity of introducing the technology and actually getting it through the gauntlet of introduction to whether it's individual hospitals, health systems, ambulatory surgery centers, or even privately owned labs and institutions." — Ryan O'Mahoney"In this modern day, and the economic climate, and the power that administration has... the clinical is not enough." — Ryan O'MahoneyTakeawaysCommercial StrategyEngage Commercial Strategy Pre-Clearance: Begin structuring your commercial roadmap and refining your Ideal Customer Profile (ICP) 2 to 3 months before expected regulatory clearance to ensure your go-to-market execution launches seamlessly. Capital Allocation & FundraisingLeverage Fractional Expertise to De-Risk Valuation: Utilizing fractional commercial executives preserves vital runway while instilling institutional confidence in investors, signaling that the organization is prepared for real-world scaling. R&D & Product AlignmentPass the Three-Pillar Framework Before Scaling: Ensure your technology satisfies all three essential vectors before attempting commercial scale: measurable clinical differences for the patient, procedural advantages over the status quo for the practitioner, and clear economic return on investment for the administration. Market DevelopmentPre-Align Administration to Avoid Broken Pilots: Prevent your device from getting stuck in perpetual, non-revenue-generating clinical trials by engaging hospital administrators in virtual demonstrations early, tying the success metrics of the pilot directly to a formal budget proposal pathway. ReferencesCatalyst Ventures: The commercial acceleration and strategy firm founded by Ryan O'Mahoney, specializing in bringing paradigm-shifting medical technologies to global markets. Etienne Nichols: Connect with the host on LinkedIn via Etienne Nichols' LinkedIn Profile. MedTech 101 SectionThe Valley of Death (Commercialization)In the medical device space, engineers often look at the "valley of death" as the difficult phase of raising money to move from a prototype to regulatory submission. However, there is a second commercial valley of death. This is the period after you get your official clearance from regulatory bodies (like the FDA), where companies frequently run out of money because they cannot figure out how to navigate complex hospital networks, get approved by purchasing committees, and turn clinical interest into consistent sales revenue. Value Analysis Committee (VAC)Think of a hospital's Value Analysis Committee as a strict gatekeeper panel for the hospital's wallet. Years ago, if a doctor liked a medical tool, the hospital bought it. Today, a formal committee made up of administrators, finance staff, and doctors must review every new product. They analyze whether the device is truly better than what they already use, if it reduces hospital stay times, and if the financial cost makes sense against the hospital's annual budget. Feedback Call-to-ActionWe want to hear from you. Have you encountered the commercial valley of death in your own medical device journey? Do you have specific regulatory, commercial, or operational topics you want us to unpack in upcoming episodes? Drop us a line at podcast@greenlight.guru with your thoughts, questions, or guest recommendations. We read every email and look forward to delivering the personalized insights you need to confidently bring your innovations to life. SponsorsThis episode of the Global Medical Device Podcast is brought to you by Greenlight Guru, the only dedicated medical device success platform. Moving successfully from innovation through the commercial gauntlet requires total synchronization across your entire lifecycle. Greenlight Guru's modern Quality Management Software (QMS) ensures your documentation, design controls, and regulatory submittals remain audit-ready and airtight during pre-market development. Once cleared, seamlessly transition your clinical data collection into the real world using Greenlight Guru's Electronic Data Capture (EDC) solutions. Together, their QMS and EDC ecosystem empowers MedTech startups to de-risk their commercialization process, satisfy demanding institutional purchasing committees, and scale safely worldwide. Learn more at www.greenlight.guru.

In this episode, host Etienne Nichols sits down with industry veteran Mike Drues to explore a critical theme in modern MedTech: the danger of "not knowing what you don't know." The conversation centers on the growing trend of companies making avoidable, "boneheaded" mistakes despite a robust regulatory framework. Mike Drues emphasizes that while technology evolves, the fundamental responsibility for safety and effectiveness remains non-delegable. The discussion dives deep into a landmark regulatory event: the first-ever FDA warning letter issued to a company for GMP violations specifically linked to the unauthorized use of Artificial Intelligence in manufacturing. They break down the legal and ethical implications of relying on AI agents to generate specifications and production records without human oversight or process validation. Finally, the episode tackles the controversial idea of individual accountability in regulatory citations. Etienne and Ryan debate whether naming specific professionals in warning letters would curb the repeat of industry-wide errors or if internal company culture provides enough of a corrective force. It’s a sobering look at why professionals must keep their "brains at the door" and treat AI as a tool, not a replacement for human judgment. Key Timestamps00:02:15 - The "Preamble to the QSR": Why the "why" behind the regulation is more important than the "what." 00:04:10 - The Non-Delegable Rule: Why AI agents cannot hold responsibility for quality requirements. 00:07:30 - Case Study: The first FDA warning letter for AI-related GMP violations (Pure Parolia). 00:10:45 - The Quality Unit: Does the "Quality Unit" legally need to be a human being? 00:15:20 - Individual Accountability: The debate over naming names in official FDA warning letters. 00:20:45 - The Autopilot Metaphor: Comparing AI in surgery to autopilot in aviation and self-driving cars. 00:23:10 - Star Trek’s "The Ultimate Computer": Lessons from 1968 on over-delegating to technology. 00:27:15 - ClinicalTrials.gov: Analysis of the 30% non-compliance rate in clinical trial reporting. Quotes"The responsibility for meeting these requirements may not be delegated, even though the actual work may be delegated. This applies to artificial intelligence agents." - Mike Drues"True knowledge is knowing what you know and knowing what you don’t know, and most importantly, knowing the difference between the two." - Mike DruesTakeawaysRead the Preambles: Don't just follow the letter of the QMSR; read the Preambles to understand the FDA’s underlying logic and "thinking." AI is an Intern, Not a Manager: Treat AI as a "PhD-level intern." It can draft justifications or specifications, but it cannot "approve" them. Validate the AI Process: If AI is integrated into manufacturing or quality decisions, it requires process validation just like any other automated system. Human-in-the-Loop: Maintain a "Human-in-the-Loop" protocol for all regulatory submissions to prevent "garbage in, garbage out" errors. Check Clinical Reporting: Ensure all required clinical trial results are published on ClinicalTrials.gov; nearly a third of the industry is currently failing this basic requirement. ReferencesFDA Preamble to the QSR: The foundational text explaining the "why" behind quality regulations. 21 CFR Part 211.22: The regulation defining the responsibilities of the Quality Control Unit. Pure Parolia Warning Letter: The April 2026 citation regarding AI and process validation. Star Trek Episode 24 ("The Ultimate Computer"): A cultural cautionary tale on over-reliance on machines. Etienne Nichols’ LinkedIn MedTech 101: Process ValidationThink of Process Validation like a recipe for a cake. If you’re a baker, you don't just hope the cake turns out right every time; you test the oven temperature, the mixing time, and the ingredients to prove that if you follow the steps, you get a perfect cake 100% of the time. In MedTech, when a company uses AI to make decisions or manufacture parts, they must "validate" the process. This means proving that the AI (the oven) works correctly and consistently before selling the product. Claiming "the AI didn't tell me I had to test it" is like a baker saying they didn't know they had to turn the oven on because the recipe didn't mention it. Feedback Call-to-ActionWe want to hear from you! Do you think the FDA should start naming names in warning letters? Should the "Quality Unit" be legally required to be a human? Send your thoughts, reviews, or suggestions for future topics to podcast@greenlight.guru. We read every email and pride ourselves on providing personalized responses to our community. SponsorsThis episode is powered by Greenlight Guru. In an era where you cannot delegate your quality responsibility to AI, you need tools that empower your human experts. Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions provide the "regulatory logic" and data integrity needed to ensure your team stays compliant, from clinical trials through post-market surveillance. Connect your quality processes and clinical data seamlessly to avoid the "boneheaded mistakes" discussed today.

In this episode of the Global Medical Device Podcast, host Etienne Nichols sits down with John Schindler, CEO of Liquet Medical, for a "MedTech Founder 101" masterclass. With over 25 years of experience at industry giants like Atrium and Merit Medical, Schindler shares the "painful reality checks" that come when transitioning from the structured umbrella of a large corporation to the high-stakes, resource-dependent world of a startup. The conversation dives deep into the philosophy of "novel but simple" technology. Schindler explains why simplicity is often harder to fund but essential for physician adoption and long-term market success. He challenges the current industry obsession with over-engineered solutions, arguing that the pendulum is swinging back toward intuitive, easy-to-use devices that don't "break the system" of healthcare delivery. Finally, the discussion covers the tactical realities of commercialization, including the nuances of the "Valley of Death." Schindler outlines why a limited market release is often superior to broad distribution and emphasizes the importance of building strategic enterprise value through intentional clinical data that speaks to both regulatory bodies and hospital value analysis committees. Key Timestamps00:45 – Introduction to John Schindler and Liquet Medical’s mission. 02:15 – The Corporate vs. Startup Reality: Losing the safety net of big-company resources. 04:30 – Simplicity vs. Complexity: Why investors favor "shiny" tech but physicians crave simplicity. 07:50 – The MedTech Innovator Experience: Leveraging human capital and "pressure testing" your company. 10:15 – Unlearning Corporate Silos: The necessity of radical collaboration in early-stage teams. 12:40 – Clinical Data Strategies: Moving beyond "clinical wins" to hospital value analysis. 15:30 – Establishing "Soft Endpoints" for payers and rural healthcare settings. 18:20 – Negotiating as a Cash-Strapped Startup: Approaching vendors and regulatory services with humility. 21:10 – The Regulatory Chess Game: Why early engagement with the FDA prevents timeline resets. 24:35 – Commercialization and the 510(k) vs. IDE strategy. 27:15 – The Risks of Distribution Agreements: Why products "fall to the bottom of the bag." Quotes"The complexity can actually break the system in some ways. Physicians always gravitate back towards simplicity—things that are easy for them to wrap their heads around." - John SchindlerTakeawaysMaster the Holistic Approach: Founders should seek exposure to every facet of the business—sales, management, and business development—to understand how their innovation responds "in the trenches." Everything is Negotiable: Especially for cash-strapped startups, approaching regulatory and quality service providers with humility can lead to flexible contract structures that help build a strong foundation early. Clinical Data is for Post-Submission too: Don't just collect data to satisfy the FDA; identify "soft endpoints" that prove economic value to hospital value analysis committees and payers. Control Your Launch: A Limited Market Release (LMR) allows a startup to "get their nose bloodied" on a small scale, refining the sales methodology before attempting to scale nationally. Avoid the "Bottom of the Bag" Syndrome: Be cautious with large distribution agreements early on. If the sales force isn't properly incentivized or trained, your product may be ignored in favor of higher-margin legacy items. ReferencesMedTech Innovator: The world’s largest accelerator for medical device companies. Hal Stowe (Eurofins): Referenced for his recent article on the strategic value of a purposeful regulatory strategy. Etienne Nichols: Connect with the host on LinkedIn. MedTech 101: The 510(k) vs. IDEIn this episode, John mentions having a 510(k) clearance but needing an IDE trial. 510(k): Think of this as the "Me Too" pathway. You are telling the FDA your device is "substantially equivalent" to one already on the market. It gets you through the door, but often with limited claims (a "tool claim"). IDE (Investigational Device Exemption): This allows your device to be used in a clinical study to collect safety and effectiveness data. It’s like a "permit" to do the deep research needed to prove your device can treat a specific, high-stakes condition like a pulmonary embolism. SponsorsThis episode is brought to you by Greenlight Guru. For MedTech founders looking to avoid the regulatory headaches discussed today, Greenlight Guru offers the only dedicated Medical Device Success Platform. From their industry-leading QMS (Quality Management System) to their robust EDC (Electronic Data Capture) solutions, they help you move from concept to commercialization faster while staying compliant. Connect your quality data to your clinical trials to build the "ring fence" of value John Schindler discussed. Feedback Call-to-ActionWe want to hear from you. Did John’s take on simplicity change how you view your product roadmap? Do you have a "Founder 101" topic you want us to cover? Send your thoughts, reviews, and suggestions to podcast@greenlight.guru. We read every email and pride ourselves on providing personalized responses to our MedTech community.

In this episode, host Etienne Nichols sits down with Dr. Adam Saltman, Chief Medical Officer at NAMSA, to explore the treacherous "valley of death" that exists between a medical device prototype and the patient. With a unique "triple threat" perspective as a cardiothoracic surgeon, former FDA official, and industry consultant, Dr. Saltman reveals why technical brilliance often fails in the face of commercial reality. The conversation dives deep into the common pitfalls of early-stage startups, specifically the tendency to develop technology in a "tech echo chamber" without validating the unmet clinical need. Dr. Saltman shares a sobering story of a company that achieved regulatory authorization and reimbursement only to find that no one wanted to buy their product because it solved a problem clinicians didn't have. Finally, the discussion shifts to the evolving landscape of AI in healthcare. Dr. Saltman warns against "automation bias" and emphasizes that regulators and clinicians are no longer satisfied with "black box" explanations. Whether it's navigating FDA guidance or choosing between a 510(k) and a De Novo pathway, the takeaway is clear: start with the end user in mind and validate every hypothesis with real-world clinical perspective. Key Timestamps[00:01:45] Introducing Dr. Adam Saltman: The surgeon, regulator, and consultant perspective. [00:03:10] The #1 Mistake: Building a product that doesn't address an actual unmet clinical need. [00:05:40] The Echo Chamber: Why engineers must look beyond their own circles for product validation. [00:06:50] The CFO vs. The Surgeon: A cautionary tale about who actually makes the purchasing decisions in a hospital. [00:09:40] Staying Current: How to manually and digitally track the constant stream of FDA guidance documents. [00:11:45] AI in MedTech: Moving from "black box" algorithms to transparent, explainable technology. [00:13:30] The X-Ray Failure: A real-world example of AI predicting mortality based on patient location rather than clinical data. [00:15:20] Automation Bias: Why you should treat AI as an assistant, not a replacement. [00:18:15] Marketing vs. Utility: The "Billboard Effect" of surgical robots and AI features. [00:20:00] Signs of Success: How Dr. Saltman identifies startups that are likely to succeed versus those "wasting" capital. [00:23:10] Calling the Baby Ugly: The necessity of pivot-readiness and adult influence in startup management. [00:25:30] The 510(k) Trap: Why the fastest regulatory path might be your biggest commercial hurdle. Quotes"You really need to start with the end in mind and test that hypothesis. Get out of the office and go out there and talk to people and really confirm that." - Dr. Saltman"This is my assistant, not my replacement." - Dr. SaltmanTakeawaysValidate the Unmet Need: Before investing in R&D, ensure your target customer actually sees a need for the product. Technical viability does not equal market demand. Avoid the 510(k) Trap: Opting for the easiest regulatory path may pigeonhole your device into low reimbursement codes by labeling it as "the same" as existing technology. Combat Automation Bias: Never assume an AI or automated system is 100% correct. Maintain a critical eye and perform regular "smell tests" on AI-generated outputs. Engage Clinical Input Early: It is almost impossible to get professional clinical input too early, but it is very easy to seek it too late. Consider fractional clinical leadership to save costs. Identify All Stakeholders: Your user (the surgeon or nurse) is often not the purchaser (the CFO). Your evidence strategy must satisfy both. ReferencesZotero: A free reference manager Dr. Saltman uses to track and tag FDA guidance documents. The Founder’s Dilemma: A book referenced regarding the challenges of early-stage startup management and decision-making. Etienne Nichols’ LinkedIn: Connect with Etienne here. MedTech 101 Section: The 510(k) vs. De NovoThink of a 510(k) like a "Me Too" application. You are telling the FDA, "My device is just like this other one already on the market (the predicate)." It’s usually faster and cheaper. A De Novo is for "New" territory—devices that are low-to-moderate risk but don't have a direct twin already on the market. While 510(k) is the path of least resistance, it can be a "trap" because it makes it harder to argue that your device is unique enough to deserve a higher price or better insurance coverage. Feedback Call-to-ActionWe want to hear from you! Do you have a MedTech success story or a regulatory hurdle you're currently facing? Send your feedback, reviews, and topic suggestions to podcast@greenlight.guru. We read every email and love providing personalized responses to our community of innovators. SponsorsThis episode is brought to you by Greenlight Guru. When navigating the "valley of death" between prototype and patient, you need a robust ecosystem to manage your data. Greenlight Guru offers industry-leading QMS (Quality Management Software) to keep your compliance on track and EDC (Electronic Data Capture) solutions to ensure your clinical evidence is ironclad. Whether you're avoiding the 510(k) trap or preparing for a De Novo submission, Greenlight Guru helps you close the gap with confidence.

Sustainability in the medical device industry is far more complex than simple material substitution. It involves a rigorous balancing act between biocompatibility, regulatory requirements, and supply chain logistics. Etienne Nichols sits down with Lucas Pianegonda, founder of Gradical, to explore why the industry is finally moving toward greener solutions and how companies can adapt without sacrificing technical performance. The conversation identifies four primary drivers for this shift: investor pressure, customer demand from hospital systems, competitive "FOMO," and tightening European regulations like the EU Green Deal. Lucas breaks down the concept of Scope 3 emissions, revealing that materials and the device use-phase often account for over 90% of a company’s carbon footprint, making material selection the most significant lever for change. Finally, the episode provides a pragmatic roadmap for implementation. From the "mass balance" approach that avoids re-validation to the strategic replacement of over-engineered "Ferrari" plastics like PEEK, Lucas explains how sustainability can serve as a market tie-breaker. The discussion emphasizes that the goal isn't just a "green premium" but a triple bottom line that aligns cost, patient outcomes, and environmental health. Key Timestamps00:45 – The complexity of sustainability in a regulated environment. 02:15 – The four pillars driving MedTech sustainability: Investors, Customers, Competition, and Regulation. 04:30 – Understanding Scope 3 emissions: Why materials represent 48% of the lever. 08:12 – The "Society and Trees" philosophy: Lucas’s personal motivation for founding Gradical. 12:45 – Market Advantages: How the "Echo Inject" startup captured industry attention. 15:30 – Identifying over-engineered "Ferrari" plastics: The PEEK vs. Polypropylene debate. 18:22 – Case Study: Ambu’s strategy in single-use endoscopy and environmental LCA results. 21:10 – The "Mass Balance" solution: Dropping in sustainable feedstocks without re-validation. 24:45 – Biocompatibility: Why it’s a device property, not a material property. 27:15 – Global Perspectives: The NHS 2027 net-zero roadmap and California’s influence in the US. 31:20 – Sustainability as a tie-breaker: Gaining market share through tender wins. Quotes"Society is stable when old men plant trees whose shadow they will never sit under." - Lucas Pianegonda"Biocompatibility is a device property and not a material property." - Lucas PianegondaTakeawaysLeverage the Mass Balance Approach: Utilize ISCC+ certified materials to swap fossil-fuel feedstocks for bio-based ones, maintaining identical chemical properties to avoid costly regulatory re-validation. Audit Over-Engineered Parts: Identify components made from high-cost, high-impact plastics (like PEEK) that could be replaced by optimized, lower-impact polymers without losing functional integrity. Prepare for the NHS 2027 Deadline: Suppliers must have a verified net-zero plan by 2027 to remain eligible for NHS contracts, a trend likely to spread across Europe. Design for the Triple Bottom Line: Aim for the intersection of cost savings, clinical performance, and eco-friendliness to ensure product viability. ReferencesGradical: Lucas Pianegonda’s firm specializing in sustainable material selection. ISCC (International Sustainability and Carbon Certification): The leading certification system for mass balance supply chains. Ambu: A pioneer in sustainable single-use endoscopy mentioned as a strategic success story. Etienne Nichols’ LinkedIn: Connect with Etienne MedTech 101: Mass BalanceThink of the electrical grid: you might pay for "solar power," but the specific electrons hitting your toaster aren't necessarily from a solar panel. However, by paying for it, you ensure that a certain amount of solar energy is added to the total mix. Mass Balance in plastics works the same way. Sustainable feedstocks (like used cooking oil) are mixed into the refinery with oil. While you can't track the "green" molecules to the final plastic part, the system ensures that the total volume of sustainable material used matches the volume of "sustainable" plastic sold. SponsorsThis episode is brought to you by Greenlight Guru. Whether you are transitioning to sustainable materials or launching a new innovation, Greenlight Guru’s QMS (Quality Management System) helps you maintain compliance throughout material changes, while their EDC (Electronic Data Capture) solutions ensure your clinical data is robust and audit-ready. Feedback Call-to-ActionWe want to hear from you! How is your team tackling the sustainability challenge? Send your thoughts, guest suggestions, or specific material questions to podcast@greenlight.guru. We read every email and love tailoring our episodes to your professional needs.

In this episode, host Etienne Nichols speaks directly to professionals in industries like automotive, aerospace, and manufacturing who are looking to transition into MedTech. Drawing from his own experience moving from aerospace to medical devices, Etienne demystifies the industry’s high barriers to entry and explains why your existing skills are more valuable than you might think. The conversation centers on the "three doors" of entry: Quality, Regulatory Affairs, and Product Development. While each path has unique requirements, Etienne emphasizes that foundational skills like project management, root cause analysis, and technical writing are the true drivers of success. He also clarifies the shift in mindset required to work in a highly regulated environment where "move fast and break things" is replaced by rigorous documentation and risk-management protocols. Finally, Etienne provides a five-step roadmap for career switchers, ranging from learning the regulatory language to networking with intention. He concludes with a powerful reminder that technical competence is only the entry fee; long-term career growth in MedTech requires mastering the "layer above"—communication, visibility, and storytelling. Key Timestamps00:00 – The "career switcher" mindset: Why MedTech is a stable and fulfilling choice. 03:15 – The Regulatory Universe: Comparing IATF 16949 and AS9100 to ISO 13485 and 21 CFR Part 820. 06:42 – Door #1: Quality. Roles in quality systems, auditing, and why "document control is document control." 10:15 – Door #2: Regulatory Affairs. How to break into the most specialized sector of MedTech. 13:50 – Door #3: Product Development. Designing with guardrails and the importance of design controls. 17:30 – Transferable Skills: Project management (PMP), root cause analysis, and process validation (IQ/OQ/PQ). 22:10 – What doesn't transfer: The reality of MedTech speed and the death of "good enough" thinking. 26:45 – 5 Steps to making the jump: Language, credentials, networking, targeting, and honesty. 32:15 – The Layer Above Competence: Navigating workplace politics and the "Workplace Poker" philosophy. Quotes"In automotive, a quality failure means a recall. In MedTech, a quality failure could mean that somebody gets hurt. It changes the math." - Etienne Nichols"If we didn't document it, it didn't happen. Getting used to that level of rigor is one of the biggest adjustments career switchers face." - Etienne NicholsTakeawaysFocus on the QMS Foundations: If you are coming from a quality background, prioritize learning ISO 13485 and ISO 14971 (Risk Management). These are the global languages of MedTech quality. Document Everything: Successful MedTech professionals must transition from "casual" documentation (emails/memos) to formal Design Controls, where every input has a verified output. Leverage Cross-Industry Skills: Lean on your experience in Six Sigma, Root Cause Analysis (RCA), and Process Validation; the statistics are the same, even if the regulatory "overlay" is different. Target Mid-Sized Companies: While big names like J&J are attractive, medium-sized companies or Contract Manufacturers (CMOs) often provide better mentorship and a faster learning curve for newcomers. Master "The Layer Above": Technical skills get you hired, but visibility and the ability to communicate technical risks to non-technical stakeholders are what lead to promotions. MedTech 101 SectionIQ/OQ/PQ (Process Validation) Think of this like baking a signature cake for a high-stakes competition. IQ (Installation Qualification): Did you plug the oven in correctly and is it the right model? (Is the equipment installed right?) OQ (Operational Qualification): Does the oven actually hit 350°F when you turn the dial, and does it stay there? (Does it work at its limits?) PQ (Performance Qualification): Can you bake ten perfect cakes in a row using your actual ingredients and staff? (Does the process consistently produce a good product?) ReferencesISO 13485:2016: The international standard for medical device quality management systems. 21 CFR Part 820 / QMSR: The FDA’s requirements for medical device manufacturers. RAPS (Regulatory Affairs Professionals Society): Recommended for Regulatory Affairs Certification (RAC). Workplace Poker by Dan Rust: A recommended read for navigating office politics and career growth. Etienne Nichols' LinkedIn: Connect with Etienne here SponsorsThis episode is brought to you by Greenlight Guru. If you are transitioning into MedTech, you'll quickly realize that documentation is everything. Greenlight Guru offers the only dedicated Quality Management System (QMS) and Electronic Data Capture (EDC) solutions designed specifically for the medical device industry. Whether you are navigating your first clinical trial or scaling a quality system from scratch, Greenlight Guru helps you move faster while staying compliant. Feedback Call-to-ActionWe want to hear your story! Are you trying to make the jump into MedTech, or have you recently made the switch? Send your questions, topic suggestions, or feedback to podcast@greenlight.guru. Etienne reads every email and provides personalized responses to help you on your journey. We’d also love for you to leave a review on your favorite podcast platform!

In this deep-dive episode, host Etienne Nichols shifts away from the "inspiring" fluff of entrepreneurship to deliver a gritty, practical masterclass for medical device founders. Drawing from his experience judging at MedTech Innovator and speaking with hundreds of founders, Etienne highlights a sobering reality: success in this industry isn't just about having the best technology. It is about getting the right specialized experts in the room at exactly the right time to avoid the "walls" that sink most startups. The conversation centers on the critical importance of early-stage strategic planning. Etienne argues that the most important first step for any founder isn't building a prototype or filing a patent—it’s establishing a regulatory strategy. By understanding the classification and requirements of a device early on, founders can prevent the catastrophic loss of capital and time that occurs when a design doesn't match the eventual clinical or regulatory data requirements. Finally, the episode walks listeners through the transition from design to commercialization. Etienne emphasizes the "valley of death" that occurs after FDA clearance, where many companies fail because they lacked a reimbursement strategy. This episode serves as the essential recording Etienne wishes he had ten years ago, offering a comprehensive blueprint for navigating the complex MedTech ecosystem in 2026. Key Timestamps00:01:17 - The Idea Stage: Why regulatory strategy must come before the prototype. 00:03:02 - The "First Three": Essential roles for the early idea phase. 00:05:35 - Stage 2: Design and Development—The reality of design controls and ISO standards. 00:08:11 - Building your quality system and the necessity of risk management (ISO 14971). 00:09:18 - Human Factors: Why the FDA cares about the "layperson" user experience. 00:10:33 - The Manufacturing Dilemma: Why Etienne recommends a CMO over in-house production. 00:14:28 - Stage 3: Testing and Verification—Managing backlogs and accredited labs. 00:17:27 - The Biological Evaluation Plan: Why you need a biocompatibility expert. 00:19:02 - The role of the statistician in clinical data and test methods. 00:20:07 - Stage 4: Submission and Clearance—The craft of telling your regulatory story. 00:22:33 - Reimbursement Strategy: The missing link that saves businesses from the "Valley of Death." 00:24:07 - Stage 5: Commercialization—Navigating the post-clearance landscape. Quotes"Your regulatory pathway is going to determine everything. It determines your timeline, your budget, your clinical requirements... it's like eating your vegetables before you're even allowed to look at dessert." - Etienne Nichols"The companies that make it aren't always the ones with the best technology; they're the ones who get the right people in the room at the right time." - Etienne NicholsTakeawaysRegulatory First: Never spend significant capital on prototypes until you have a confirmed regulatory classification and pathway. Document from Day One: Start your design controls and document control early to avoid "recreating history," which is expensive, painful, and often leads to reverse engineering. Leverage CMO Expertise: In 2026, partnering with a Contract Manufacturing Organization (CMO) is often superior to in-house manufacturing due to their specialized knowledge in DFM (Design for Manufacturing) and process validation (IQ/OQ/PQ). Plan for Reimbursement Early: FDA clearance does not guarantee a business. Without a CPT code or a clear insurance coverage path, a device cannot be commercially successful. ReferencesISO 13485:2016: The international standard for medical device quality management systems. ISO 14971: The essential standard for the application of risk management to medical devices. ISO 10993: The standard series for the biological evaluation of medical devices. IEC 60601 & 62304: Standards governing electrical safety and software life cycle processes. Greenlight Guru: Provides QMS (Quality Management System) and EDC (Electronic Data Capture) solutions specifically designed for MedTech. Etienne Nichols' LinkedIn: Connect with Etienne for expert connections and industry insights. MedTech 101 SectionDesign Controls Think of design controls like a rigorous "paper trail" for a recipe. If you were baking a cake for a grocery store, you couldn't just throw ingredients in a bowl. You would need to prove what the ingredients were (Inputs), show that the final cake matches the recipe (Verification), and confirm that people actually enjoy eating it (Validation). In MedTech, this process ensures the device you built is exactly what you intended to build and that it actually helps the patient. 510(k) vs. De Novo vs. PMA 510(k) (Cleared): Your device is "substantially equivalent" to something already on the market (a predicate). De Novo (Granted): Your device is low-to-moderate risk, but there is no existing predicate. PMA (Approved): For high-risk, Class 3 devices (like a pacemaker). This is the most stringent path and almost always requires clinical trials. SponsorsThis episode is brought to you by Greenlight Guru. For founders navigating the design and development stage, Greenlight Guru offers a dedicated Medical Device QMS software that makes documenting design controls and risk management seamless. As you move into clinical testing, their EDC (Electronic Data Capture) solutions ensure your clinical data is high-quality and submission-ready. Align your technology with your regulatory strategy by visiting greenlight.guru. Feedback Call-to-ActionWe want to hear from you! Whether you have questions about the five stages or suggestions for a deep dive into reimbursement, send your thoughts to podcast@greenlight.guru. Etienne reads every email and provides personalized responses to help you on your founder journey. Did this roadmap help you? Please leave us a review on Apple Podcasts or Spotify—it helps other MedTech founders find the show!

In this episode, Etienne Nichols sits down with Staci Miller, a Human Factors and UX Strategist at GenUX, to demystify the role of human factors (HF) in the medical device regulatory pathway. Staci explains that many companies mistakenly treat HF as a "box-checking" exercise late in development, leading to costly submission delays or rejections when the FDA finds the documentation fails to tell a cohesive safety story. The conversation dives deep into the technical distinctions between a Use-Related Risk Analysis (URRA) and a User Failure Mode and Effects Analysis (uFMEA). Staci provides a framework for deciding which approach fits your product, emphasizing that while large conglomerates with post-market data may lean toward uFMEAs, startups and those with novel devices should prioritize the URRA to effectively map out user interactions without the crutch of existing market data. Finally, Staci addresses one of the most persistent myths in the industry: the idea that clinical trial data can replace human factors validation. She clarifies that while the two can overlap in specific, premeditated circumstances (such as complex implants like aortic valves), they serve entirely different masters—one focused on clinical efficacy and the other on the safety of the user interface across diverse environments. Key Timestamps04:12 – The common disconnect: Integrating Human Factors into ISO 14971 risk management. 06:45 – URRA vs. uFMEA: How to choose based on your post-market data and predicate device status. 10:30 – The "Definition of Done": Tracking the lifecycle of HF documentation from phase zero to market release. 13:15 – System errors vs. Use errors: How to identify root causes during summative studies. 18:50 – The "Clinical Trial Myth": Why efficacy data is not the same as usability validation. 22:10 – Design Inputs vs. Design Outputs: The "Blueprint and the House" analogy for FDA submissions. 25:40 – The impact of the "Use Environment": Testing for movement in ambulances and lighting in radiology suites. Quotes"The FDA doesn't put things out there just to have a good time... If they've made human factors a requirement and you're treating it as a 'suggestion,' you're giving yourself enough rope to hang yourself." - Staci Miller "People are obsessed with the product themselves—the design outputs. But the FDA wants to see the design inputs. They want to see the blueprints of how you built that house, not just the wallpaper." - Staci Miller TakeawaysPremeditation is Key: If you intend to use clinical trial data for HF validation, it must be planned in the protocol from the start; you cannot retroactively claim clinical data satisfies usability requirements. Map User Groups Early: Distinguish clearly between primary and secondary users. Bloating user sets without explaining how or why they engage with the device complicates your risk profile. Environment Matters: Documentation must account for the physical "10,000-foot view," including noise, lighting, and motion (e.g., an ambulance), as these are often where critical use errors occur. HF is Risk Management: Human factors should not live in a silo. It must align with the scales of harm (negligible to catastrophic) defined in ISO 14971 and work in tandem with Quality and Regulatory teams. ReferencesISO 14971: The global standard for the application of risk management to medical devices. FDA Human Factors Guidance: The primary document outlining expectations for usability testing and documentation. Etienne Nichols: LinkedIn Profile MedTech 101: URRA vs. uFMEAThink of a uFMEA (User Failure Mode and Effects Analysis) like a car manufacturer looking at an old model to see why the brakes failed in the past—it relies on known data to fix specific parts. A URRA (Use-Related Risk Analysis) is like teaching someone to drive a brand-new type of vehicle (like a spaceship) for the first time. Since you don't have "crash data" yet, you have to carefully map out every single step the pilot takes and imagine every possible way they could push the wrong button in the heat of the moment. SponsorsGreenlight Guru: This episode is brought to you by Greenlight Guru, the only quality management platform designed specifically for the medical device industry. Whether you need to manage your QMS to stay compliant with ISO 14971 or streamline your clinical data through their EDC solutions, Greenlight Guru helps you move faster with less risk. Feedback Call-to-ActionWe want to hear from you! Do you have questions about your specific regulatory pathway or a topic you’d like us to cover? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, or suggestions to podcast@greenlight.guru.

In this episode, Etienne Nichols sits down with regulatory expert Mike Drues, President of Vascular Sciences, to discuss the "culture shock" international medical device companies face when entering the U.S. market. They challenge the traditional assumption that a device should always launch outside the U.S. first, noting that shifting regulatory landscapes—especially in Europe—have made the U.S. a more attractive primary entry point for many. The conversation pivots to the technical and strategic nuances of "same device, different claims." Mike explains that if a device maintains the same design but utilizes different labeling or indications for use across borders, it is technically a different device in the eyes of regulators. This creates significant complexity for Quality Management Systems and post-market surveillance, particularly concerning reporting requirements for Class III (PMA) devices. Finally, the duo explores the "trap of equivalency," where companies mistakenly assume that a CE Mark or other international approval guarantees a smooth path through the FDA. From differing consensus standards to the strategic use of OUS (Outside US) clinical data, the episode provides a roadmap for global players to synchronize their regulatory and reimbursement strategies early in the development lifecycle. Key Timestamps01:45 - Challenging the assumption: Should you always launch outside the US first? 04:12 - Defining the "International Company": Why every developer should think globally from day one. 05:30 - The Labeling Trap: Why the same hardware with different claims is a different device. 07:50 - Post-market surveillance nuances: Reporting OUS issues in a US PMA submission. 11:15 - The "Sniff Test": Does a CE Mark actually help you with the FDA? 12:40 - Leveraging Real-World Evidence (RWE) from international markets for US submissions. 14:30 - The "Species Expansion" concept: Applying regulatory logic across different use cases. 16:15 - Consensus Standards: Why the FDA might not recognize the "most current" version of a standard. 20:00 - International Regulatory Strategy: Calculating the "lowest common denominator" for multi-country launches. 25:20 - Using 100% OUS clinical data for FDA submissions: The three essential caveats. Quotes"If you’re marketing the same device—same design, same materials—but the labeling and claims are different in the EU versus the US, then technically, it is not the same device." - Mike Drues"The regulatory logic is agnostic of the scenario. Whether it's a label expansion or a 'species expansion' from a dog to a human, the underlying logic remains the same." - Mike DruesTakeawaysSync Your Standards: Do not assume the FDA recognizes the same version of a standard (e.g., ISO 10993-1) as international bodies. Always verify via the CDRH Recognized Consensus Standards database. Design for the "Lowest Common Denominator": Identify your top 3–5 target markets early and pool their requirements to avoid redundant benchtop or clinical testing. Rethink Clinical Trials: While the FDA prefers domestic data, OUS data can be used if you can prove the patient population and user profiles (physicians/nurses) are representative of the US demographic. Anticipate "Off-Label" Pressure: If you market a device in Canada with claims not yet approved in the US, be prepared for US clinicians to find that information online and ask for "anticipated off-label use." ReferencesFDA Recognized Consensus Standards Database: Essential tool for verifying which versions of international standards the FDA currently accepts. Greenlight Guru QMS & EDC: Solutions for managing complex, multi-region quality systems and clinical data. Etienne Nichols’ LinkedIn: Connect with the host for more MedTech insights. MedTech 101: Label ExpansionThink of Label Expansion like a smartphone software update. The hardware (the phone) stays the same, but the update allows the phone to do something it couldn't do before—like a new photography mode. In MedTech, if you have a stent approved for use in the leg (the "old label") and you want to use that same stent in the heart, you apply for a "label expansion." You aren't changing the device; you're just proving it’s safe and effective for a new job. Sponsors: Greenlight GuruThis episode is brought to you by Greenlight Guru. Navigating international waters requires a robust foundation. Greenlight Guru’s Quality Management Software (QMS) helps you maintain a "single source of truth" for your design history files and labeling, while their Electronic Data Capture (EDC) solution streamlines the collection of the clinical data you'll need to satisfy both the FDA and international regulators. Whether you are managing post-market surveillance for a PMA or running a multi-center global trial, Greenlight Guru has you covered. Feedback Call-to-ActionWe want to hear from you! Did this episode change your mind about your international launch strategy? Do you have a "culture shock" story from bringing a device to the US? Send your thoughts, reviews, or topic suggestions to podcast@greenlight.guru. We read every email and love providing personalized responses to our listeners.

This episode features Ivanny Franklin, Managing Partner at MedSight Capital, who brings a wealth of experience from her background in molecular biology and her decade-long tenure at NAMSA. The conversation centers on the shifting paradigms of medical device investment, specifically how the industry is moving away from service-based models toward a focus on clinical outcomes. Etienne and Ivanny explore the critical intersection of global regulatory bodies—such as the NMPA in China and the FDA in the US—and the necessity of a cohesive clinical evidence strategy. Ivanny emphasizes that for startups, understanding market-specific data requirements is not just a regulatory hurdle but a fundamental component of commercialization and investor conviction. The discussion also dives into the "patient empowerment" movement, fueled by the convergence of wearables, AI, and at-home monitoring. Ivanny shares her bullish outlook on technologies that give patients control over their data, while acknowledging the tension this creates for physicians and the ongoing need for rigorous regulatory oversight to ensure safety and effectiveness. Key Timestamps[03:15] Global Regulatory Strategy: Insights into the NMPA (formerly CFDA) and why China requires in-country clinical evidence. [07:42] Leveraging Data: How to run a single clinical trial to satisfy multiple global regulatory bodies. [10:18] The At-Home Monitoring Shift: The rise of wearables and OTC testing in the wake of COVID-19. [13:45] The "Data Gap": Addressing the friction between patient-gathered data and physician adoption. [18:22] Investment Non-Negotiables: Why revenue-generating companies and clear regulatory classifications are key for MedSight Capital. [23:10] Diligence and Deception: The importance of honesty regarding reimbursement codes and 510(k) vs. PMA paths. [27:45] SPV vs. Hedge Fund Models: A breakdown of how Special Purpose Vehicles allow family offices to be nimble in MedTech. Quotes"FDA and NMPA, for example, are quite strict in clinical evidence coming from in-country... as a startup, you really need to understand can we run a single trial with multiple global sites to achieve clearance cohesively." - Ivanny Franklin"I’m an advocate for [at-home monitoring]. I do think that’s the future. However, there is concern around what types of information should patients be receiving and how are they going to act on that information?" - Ivanny FranklinTakeawaysRegulatory is the Roadmap: An investment is often "de-risked" based on the clarity of the regulatory path. If a founder cannot distinguish between a 510(k) and a PMA, it is a major red flag for investors. Harmonize Your Trials: To achieve "economies of scale" in clinical evidence, work with consultants to design trials that meet the stringent requirements of both the FDA and international bodies like the NMPA early on. Commercial Scalability over Hype: For revenue-generating companies, investors are less concerned with the "idea" and more focused on physician retention, training, and the cost of scaling the sales team. Honesty in Reimbursement: Never "make up" or guess CPT codes. Investors utilize experts (like ex-FDA personnel) to pressure-test your reimbursement strategy during diligence. ReferencesNMPA (National Medical Products Administration): The primary regulatory body for China (formerly the CFDA). NAMSA: A world-leading Medical Device CRO mentioned as Ivanny’s former professional home. LSI (Life Science Intelligence): The upcoming conference mentioned where Etienne and Ivanny will speak on a panel. Greenlight Guru: The preferred platform for QMS & EDC solutions to manage medical device quality and clinical data. Etienne Nichols: Connect on LinkedIn. MedTech 101: SPV (Special Purpose Vehicle)Think of a Special Purpose Vehicle (SPV) like a "carpool" for investors. Instead of a massive bus (a Hedge Fund) that picks up everyone's money and decides where to go over several years, an SPV is a single car created for one specific trip—in this case, one specific company. Investors put their money into the SPV, and the SPV makes one investment in one startup. This allows smaller investors or family offices to pool their resources together to act as one large "passenger" on a company's cap table. SponsorsThis episode is brought to you by Greenlight Guru. Moving from a "service-based" model to an "outcome-based" model requires impeccable data and quality management. Greenlight Guru offers both QMS (Quality Management System) and EDC (Electronic Data Capture) solutions designed specifically for the medical device industry. Whether you are gathering clinical evidence for an NMPA submission or scaling a revenue-generating product, Greenlight Guru helps you stay compliant and efficient. Feedback Call-to-ActionWe want to hear from you! Did this breakdown of investment vehicles help you? Do you have suggestions for future MedTech topics? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, and questions to podcast@greenlight.guru.

In this episode, Etienne Nichols sits down with Edwin Lindsay, a seasoned MedTech operator and QARA leader, to discuss the systemic challenges facing the pediatric medical device market. Following a personal experience in a neonatal ward, Edwin highlights the stark reality that many pediatric treatments rely on adult devices adapted off-label, often leading to safety risks and clinical inefficiencies. The conversation delves into the "mismatch" of the pediatric market: these devices require the same rigorous regulatory and quality standards as adult products but offer significantly lower financial upside due to smaller patient populations. This creates a barrier for investors and manufacturers, leaving clinicians and nurses to "work miracles" with tools that aren't always fit for purpose. Despite these hurdles, Edwin shares an optimistic vision for the future. He discusses his initiative to build a collaborative network of experts—including regulatory consultants, testing houses, and grant writers—willing to provide pro-bono or at-cost support for pediatric startups. The goal is to create a streamlined regulatory roadmap that prioritizes patient safety without the prohibitive costs that currently stall innovation. Key Timestamps00:45 – The "Pediatric Gap": Why pediatric devices have adult-level requirements but lower ROI. 03:12 – Personal Insight: Edwin’s experience in the hospital and the "Guinness philosophy" of giving back. 05:30 – The danger of adhesives and adapting adult materials for newborn skin. 08:15 – Building a pediatric volunteer network: Testing houses and consultancies stepping up. 11:40 – Regulatory Roadmaps: Navigating the age variability from premature infants to adolescents. 14:50 – Off-label usage risks and the "mindset shift" required for manufacturers. 18:25 – Micro-timestamp: The FDA’s Humanitarian Device Exemption (HDE) and P-Sub programs. 21:10 – Real-world clinical friction: Alarm fatigue and sensor sensitivity in NICU settings. 25:40 – The hidden costs: Manufacturing complexity, multiple SKUs, and low-volume production. Quotes"We need to give clinicians the correct tools to work their miracles. They don't want to use products off-label; they want devices actually designed for the children they are saving." - Edwin Lindsay"If you have a pediatric project, there is a community behind you. We are breaking down the barriers of risk and cost because these babies deserve a chance." - Edwin LindsayTakeawaysRegulatory Flexibility: Utilize specific FDA pathways like the Humanitarian Device Exemption (HDE) and the Pediatric Submissions (P-Sub) program to gain early feedback and specialized guidance. Collaborative Cost-Sharing: Seek out "altruistic" partners; many testing houses and manufacturers are willing to work at-cost or under different financial models for pediatric-specific innovations. Design for Sensitivity: Pediatric innovation isn't just about miniaturizing adult tech—it requires solving unique issues like alarm fatigue and skin sensitivity (e.g., non-damaging adhesives). Workflow Integration: Engage the "head nurse" early in R&D to ensure the device fits into the high-stress environment of a pediatric ward without adding to clinical fatigue. ReferencesFDA HDE Program: A regulatory pathway for devices intended for diseases or conditions that affect small populations. Greenlight Guru: The industry-leading platform for QMS & EDC solutions, helping MedTech companies maintain compliance while accelerating pediatric product development. Etienne Nichols on LinkedIn: Connect with Etienne for more MedTech insights. MedTech 101: Off-Label UseIn the medical device world, "Off-Label" means using a device for a purpose, or on a patient population (like infants), that the FDA has not officially cleared. Think of it like this: Imagine you have a high-tech hiking boot designed for a grown man, but you have to put it on a toddler because no one makes toddler-sized hiking boots. You might be able to make it stay on with extra socks and tape, but it won't support the child’s foot correctly and might cause them to trip. In pediatrics, doctors often have to "tape the boot" because specialized devices simply don't exist. Feedback Call-to-ActionWe want to hear from you! Are you working on a pediatric breakthrough, or have you faced challenges in this niche market? Whether you have a topic suggestion or a question for Edwin, send us an email at podcast@greenlight.guru. We read every message and pride ourselves on providing personalized responses to our community. SponsorsThis episode is brought to you by Greenlight Guru. Navigating the complex regulatory landscape of pediatric devices requires a robust foundation. Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions are specifically designed to help MedTech innovators manage risk and clinical data with precision. Whether you are a one-person startup or a global entity, Greenlight Guru helps you get safe, effective technology to patients faster.

In this episode, Etienne Nichols sits down with Dr. Kristy Katzenmeyer-Pleuss, President and Founder of KP Medical Device Consulting, to unpack the complexities of the medical device life cycle. The conversation centers on how manufacturers often overlook critical phases of a product’s journey, such as transportation, shelf life, and the decommissioning phase, focusing instead solely on the point of patient use. Dr. Katzenmeyer-Pleuss highlights the significance of the upcoming ISO 10993-1:2025 standard and its renewed emphasis on life cycle-based risk assessments. She explains how the transition between global markets—particularly between the EU and the US—can lead to unexpected FDA deficiencies when manufacturers rely on justifications that worked for notified bodies but do not meet more stringent FDA testing expectations for reusable or in situ curing devices. The discussion concludes with actionable advice on early design decisions, such as narrowing down material suppliers and reprocessing options to reduce testing burdens. They also explore the critical need for cross-functional communication and quality system integration to ensure that learnings from one project or regulatory interaction are captured and applied across a company’s entire portfolio. Key Timestamps01:45 – Introduction of Dr. Kristy Katzenmeyer-Pleuss and the mission of KP Medical Device Consulting. 04:12 – Defining the Medical Device Life Cycle: Concept to decommissioning and the "hidden" phases in between. 05:30 – ISO 10993-1:2025: The impact of the new biological evaluation standard on risk-based approaches. 09:15 – Global Regulatory Discrepancies: Why a device approved in Europe might face hurdles at the FDA regarding "worst-case" testing. 13:40 – Reusable Devices & Reprocessing: Managing the "permutation explosion" of cleaning agents and sterilization cycles. 17:22 – Early Design Decisions: How limiting options in the IFU can significantly decrease your regulatory testing burden. 21:05 – In Situ Curing Devices: The unique testing challenges of materials that change states during use. 25:10 – Quality System Integration: Strategies for linking regulatory deficiencies and materials across multiple projects. Quotes"The life cycle is really the concept of the medical device from when it’s a concept all the way through to the end where you are disposing or decommissioning... shelf life and transport are steps that usually don’t get a lot of focus, but they are very important." - Dr. Katzenmeyer-Pleuss"You might have one device where literally they don’t ask these questions at all, and then other times they’re very, very picky... the longer you go in that process, the harder it is to pivot without spending a lot of time and money." - Dr. Katzenmeyer-PleussTakeawaysFront-load Risk Assessments: Don’t wait for FDA deficiencies to consider how shelf life or reprocessing affects device safety; integrate these into the biological evaluation plan from day one. The "Worst-Case" Strategy: When designing testing protocols for reusable devices, aim for a "worst-case" scenario that covers future iterations or additional suppliers to avoid redundant, expensive re-testing. Standardize Your IFU Early: Providing users with infinite cleaning or sterilization options creates an exponential increase in testing requirements; narrow these down to the essentials to streamline market entry. Break the Silos: Use your QMS to link specific material risks or regulatory feedback across different project teams so that knowledge isn't lost when personnel leave. ReferencesISO 10993-1:2025: The updated international standard for the biological evaluation of medical devices within a risk management process. Etienne Nichols on LinkedIn: Connect with the host for more MedTech insights. MedTech 101: In Situ CuringIn this episode, Dr. Katzenmeyer-Pleuss mentions In Situ Curing. Think of this like a medical-grade "liquid bandage" or dental filling. The device starts as a liquid or gel and is applied to the body, where it then hardens into a solid "in the spot" (in situ). From a regulatory standpoint, this is complex because you aren't just testing one device; you have to test the safety of the liquid, the safety of the solid, and any chemicals released during the hardening process. It is essentially three devices in one when it comes to testing. SponsorsThis episode is brought to you by Greenlight Guru. When navigating the complex life cycle of a medical device—from the initial risk assessments discussed today to post-market surveillance—you need a unified system. Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions work together to ensure your data is linked, your testing is documented, and your clinical trials are seamless. By connecting your quality and clinical data, you can avoid the "disjointed" project management pitfalls Etienne and Kristy discussed. Feedback Call-to-ActionWhat are your biggest hurdles in managing the full medical device life cycle? We want to hear from you. Whether it's a specific regulatory challenge or a topic suggestion for a future guest, send your thoughts to podcast@greenlight.guru. We read every email and pride ourselves on giving personalized responses to our MedTech community.

In this episode, Etienne Nichols sits down with Thor Rollins, a leader at Nelson Labs and the convener of the committee revising ISO 10993-1. The conversation centers on the newest 2025 version of the standard, which represents a massive philosophical shift from a "checkbox" testing mentality to a rigorous, risk-based approach aligned with ISO 14971. Rollins explains that modern medical devices are far more complex than the metal and hard plastics of the past. With the rise of degradable materials, coatings, and nanomaterials, traditional animal testing often fails to provide the best science. The new standard introduces critical concepts such as biological risk estimation, foreseeable misuse, and a comprehensive lifecycle evaluation that looks beyond "time zero" safety. The duo also discusses the practical implications for manufacturers, including the controversial requirement to evaluate biocompatibility at the end of a product's lifecycle—a particular challenge for reprocessed devices. Rollins provides insider knowledge on the US’s stance on the revision, the timeline for FDA recognition, and how companies can leverage biological equivalence to potentially reduce their testing burden. Key Timestamps01:45 – The shift from "checkboxing" to a risk-based approach. 03:10 – The rapid timeline of the 2025 revision and the influence of ISO 14971. 04:22 – Lifecycle Evaluation: Assessing safety beyond the "brand new" state. 06:50 – Chronic toxicity vs. acute reactions: Why front-end evaluation matters. 08:15 – Foreseeable Misuse: When doctors use scopes outside their intended anatomy. 12:10 – The concept of Bioequivalence: Using existing data to justify reduced testing. 13:45 – Breakthrough: The removal of material-mediated pyrogenicity testing for known materials. 15:30 – Why the US voted "No" on the current draft: A call for better guidance. 18:50 – Notified Bodies and MDR: The 2025 version as "State of the Art." 21:15 – Practical chemistry tests for aging polymers (DSC, GPC, FTIR). 25:40 – Advice for small vs. large companies on building material databases. Quotes"The testing that we developed back in the 50s and 60s actually doesn't really work the best with some of these complex devices... we've been moving the standard away from what we call checkboxing." - Thor Rollins"I only say that expensive tests always impact innovation. We don't want to over-test, but we want to do the right tests." - Thor RollinsTakeawaysLifecycle is the New Frontier: You must now evaluate biocompatibility throughout the product's life, especially for reprocessed devices that may degrade after hundreds of cleaning cycles. Foreseeable Misuse is a Regulatory Reality: If it is likely a clinician will use your device off-label (e.g., a pulmonary scope used in vascular applications), you must account for that biological risk in your assessment. Leverage Bioequivalence: Stop testing the same stainless steel or titanium repeatedly. Use existing data and internal databases to justify "no testing" for known materials and processes. Partner with Expertise: Because the standard is less prescriptive and more risk-based, the quality of your Biological Evaluation Plan (BEP) depends entirely on the expertise of the person writing it. Chemistry over Animals: Whenever possible, use chemistry (Extractables & Leachables) and in vitro methods to replace legacy animal tests, as the 2025 revision officially begins to phase out certain animal-based requirements. ReferencesISO 10993-1:2025: The primary global standard for the biological evaluation of medical devices. ISO 14971: The standard for the application of risk management to medical devices, now heavily integrated into 10993-1. Nelson Labs: The laboratory where Thor Rollins leads biocompatibility strategy. Etienne Nichols: Connect with Etienne on LinkedIn. MedTech 101: BioequivalenceThink of bioequivalence like buying a generic medication versus a brand-name one. If you know the ingredients (materials) and the way they are manufactured (processes) are identical to a device that has already been proven safe on the market, you shouldn't have to re-run expensive, time-consuming tests. In MedTech, this means showing that your "New Device B" is biologically the same as your "Proven Device A" because they use the same grade of titanium and the same sterilization method. SponsorsThis episode is brought to you by Greenlight Guru. As the industry shifts toward a risk-based approach as seen in ISO 10993-1:2025, having a centralized source of truth is vital. Greenlight Guru's QMS (Quality Management System) allows you to integrate risk management directly into your design process, while their EDC (Electronic Data Capture) solution helps you gather the clinical evidence needed to prove long-term safety. When your risk assessments and clinical data live in the same ecosystem, "state of the art" compliance becomes a standard, not a struggle. Feedback Call-to-ActionWe want to hear from you! How is your team preparing for the 2025 revision of ISO 10993-1? Are you concerned about the lifecycle evaluation requirements? Send your thoughts, questions, or topic suggestions to podcast@greenlight.guru. We read every email and love providing personalized responses to our community.

This episode explores the transition from the Quality System Regulation (QSR) to the Quality Management System Regulation (QMSR) and the foundational elements required for medical device compliance. Host Etienne Nichols and guest Mike Drues discuss the philosophy of building a usable system rather than a "museum of SOPs," emphasizing that the standard list of QMS sections should be viewed as a starting point rather than an exhaustive checklist. The conversation examines the critical differences between 510(k), De Novo, and PMA pathways regarding manufacturing requirements. While a 510(k) submission may not strictly require detailed manufacturing information at the time of filing, Mike explains why companies must remain audit-ready from the moment they register their establishment with the FDA. The discussion clarifies the timing of registration and the "radar" companies enter once they become commercially active. Finally, the dialogue focuses on a "triage" approach for resource-constrained startups. By prioritizing Design Controls and Risk Management during early development, teams can remain compliant and ethical without over-investing in post-market systems, such as complaint handling, before they have a product on the market. Mike warns against the dangers of "copy-and-paste" quality systems, urging manufacturers to use professional judgment to tailor their processes to their specific technology. Key Timestamps00:00 - Introduction to QMS requirements and guest Mike Drues. 03:45 - The core sections of a QMS according to the Quality System Regulation. 05:12 - Why the QSR list is a starting point, not a stopping point. 08:20 - Regulatory vs. Ethical vs. Economical: The three legs of the medical device stool. 10:30 - Do you need a full QMS for 510(k) vs. PMA submissions? 13:15 - Understanding the timing and strategy for FDA Establishment Registration. 15:40 - The Triage Approach: Which QMS sections matter most during early development? 19:00 - The dangers of boilerplate SOPs and non-specific quality manuals. Quotes"This is a starting point. This is not a stopping point... Use your own good judgment." — Mike Drues"The goal is not really to build a museum of SOPs; the goal is a quality management system that teams will actually use." — Etienne NicholsTakeawaysPrioritize the Big Four: During the development phase, focus your limited resources on Design Controls, Risk Management, Document Control, and Supplier Quality Management. Understand Pathway Nuances: While 510(k) submissions don't require manufacturing details, you must be fully compliant and ready for inspection once your establishment is registered and the product is launched. Avoid Boilerplate SOPs: Quality systems must be specific to your organization. Including irrelevant device types or procedures in your QMS is a significant red flag for FDA inspectors. Strategic Registration: Register your establishment 60–90 days before your planned commercial launch to manage costs and stay off the FDA inspection radar until necessary. The Preamble is Key: Read the preamble of the QSR to understand the "why" behind the regulations, which allows for better justification of your quality decisions during an audit. ReferencesFDA Design Control Guidance (1997): A foundational document for medical device engineering and documentation. FDA Establishment Registration: Guidance on the timing and requirements for small business fee waivers. Etienne Nichols LinkedIn: https://www.linkedin.com/in/etiennenichols/ MedTech 101 SectionConcept: The Quality Management System (QMS) Think of a QMS like a pilot’s pre-flight checklist. You don't just "wing it" when you get into a cockpit; you have a documented process to ensure the engine is working, the fuel is full, and the wings are clear. For a small plane (a low-risk Class I device), your checklist is shorter and simpler. For a commercial jumbo jet (a high-risk Class III device), the checklist is massive and detailed. However, the goal for both is identical: ensuring the passengers (the patients) arrive safely at their destination through a repeatable, controlled process. SponsorsThis episode is brought to you by Greenlight Guru. The subject of right-sizing your quality system is exactly why Greenlight Guru offers both QMS and EDC solutions. Their Ultralight eQMS is designed specifically for fast-moving, product-led teams who need a flexible, compliant system without the overhead of a "museum of SOPs." Whether you are in early-stage R&D or preparing for a global launch, Greenlight Guru provides the tools to keep your quality and clinical data connected and audit-ready. Feedback Call-to-ActionWe want to hear from you! What are the biggest hurdles your team faces when scaling your quality system? Send your feedback, reviews, and topic suggestions to podcast@greenlight.guru. We read every email and pride ourselves on providing personalized responses to our listeners.

In this episode, host Etienne Nichols sits down with Ashkon Rasooli, founder of Ingenious Solutions and a specialist in Software as a Medical Device (SaMD). The conversation previews their upcoming session at MD&M West, focusing on the critical intersection of generative AI (GenAI) and quality assurance. While many AI applications exist in MedTech, GenAI presents unique challenges because it creates new data—text, code, or images—rather than simply classifying existing information. Ashkon breaks down the specific failure modes unique to generative models, most notably "hallucinations." He explains how these outputs can appear legitimate while being factually incorrect, and explores the cascading levels of risk this poses. The discussion moves from simple credibility issues to severe safety concerns when AI-generated data is used in critical clinical decision-making without proper guardrails. The episode concludes with a forward-looking perspective on how validation is shifting. Ashkon argues that because GenAI behavior is statistical rather than deterministic, traditional pre-market validation is no longer sufficient. Instead, a robust quality framework must include continuous post-market surveillance and real-time independent monitoring to ensure device safety and effectiveness over time. Key Timestamps01:45 - Introduction to MD&M West and the "AI Guy for SaMD," Ashkon Rasooli. 04:12 - Defining Generative AI: How it differs from traditional machine learning and image recognition. 06:30 - Hallucinations: Exploring failure modes where AI creates plausible but false data. 08:50 - The Autonomy Scale: Applying standard 34971 to determine the level of human supervision required. 12:15 - Regulatory Gaps: Why no generative AI medical devices have been cleared by the FDA yet. 15:40 - Safety by Design: Using "independent verification agents" to monitor AI outputs in real-time. 19:00 - The Shift to Post-Market Validation: Why 90% validation at launch requires 10% continuous monitoring. 22:15 - Comparing AI to Laboratory Developed Tests (LDTs) and the role of the expert user. Quotes"Hallucinations are just a very familiar form of failure modes... where the product creates sample data that doesn't actually align with reality." - Ashkon Rasooli"Your validation plan isn't just going to be a number of activities you do that gate release to market; it is actually going to be those plus a number of activities you do after market release." - Ashkon RasooliTakeawaysRight-Size Autonomy: Match the AI’s level of independence to the risk of the application. High-risk diagnostic tools should have lower autonomy (Level 1-2), while administrative tools can operate more freely. Implement Redundancy: Use a "two is one" approach by employing an independent AI verification agent to check the primary model’s output against safety guidelines before it reaches the user. Narrow the Scope: To reduce hallucinations, limit the AI's task breadth. A model asked to write a specific security requirement is more reliable than one asked to generate an entire Design History File (DHF). Prioritize Detectability: Design UI/UX features that provide the sources or "basis" for an AI's answer, allowing human users to verify the data and catch errors more easily. Continuous Surveillance: Accept that pre-market validation cannot cover all statistical outcomes; establish a post-market "watchtower" to monitor for performance shifts and user feedback trends. ReferencesISO 14971: The standard for the application of risk management to medical devices. AAMI TIR34971: Guidance on the application of ISO 14971 to machine learning in medical devices. IEC 62304: Medical device software lifecycle processes. Etienne Nichols: LinkedIn Profile MedTech 101: The Autonomy ScaleThink of the Autonomy Scale like the driver-assist features in a car. Level 1 is like a backup camera: It gives you data, but you are still 100% in control of the steering and braking. Level 5 is a fully self-driving car where you can sleep in the back seat. In MedTech, most generative AI is currently aiming for Level 2 or 3, where the AI suggests a "route" (like a diagnosis or a draft report), but a human "driver" (the doctor or engineer) must keep their hands on the wheel and verify every turn. SponsorsThis episode is brought to you by Greenlight Guru. Whether you are navigating the complexities of generative AI or traditional hardware, Greenlight Guru offers the only specialized Quality Management System (QMS) and Electronic Data Capture (EDC) solutions designed specifically for the medical device industry. By integrating your quality processes with clinical data collection, Greenlight Guru helps you move from "check-the-box" compliance to true quality. Feedback Call-to-ActionWe want to hear from you! How is your team implementing AI in your workflow? Do you have questions about the shifting regulatory landscape? Send your thoughts, reviews, or topic suggestions to podcast@greenlight.guru. We read every email and pride ourselves on providing personalized responses to our community of MedTech movers and shakers.

Dr. Jenny Hoffmann, MedTech executive and author of Open Up: Step Into the Leader You Are Meant to Be, joins host Etienne Nichols to discuss the evolution of leadership in the medical device industry. Drawing from her experience as a bioengineer and CEO, Dr. Hoffmann explains why the traditional model of the "rigid, perfect leader" is no longer sustainable. She shares her personal journey—from being one of the first IVF babies in the U.S. to navigating life-threatening health complications—and how these experiences shaped her mission to help others lead with authenticity. The conversation centers on the concept of "SOS moments," which Dr. Hoffmann defines as those critical points of distress or crisis that occur in both personal lives and product development. By applying her CEC framework—Curiosity, Empathy, and Connection—leaders can transform these high-pressure moments into stories of strength. This approach is particularly vital in MedTech, where the ultimate goal is to serve patients during their own most vulnerable SOS moments. Etienne and Jenny also explore the intersection of human leadership and emerging technology. While AI continues to streamline technical workflows, Dr. Hoffmann argues that human empathy and curiosity remain irreplaceable assets for innovation. The episode concludes with a practical look at the return on investment (ROI) for "opening up," demonstrating how personal connection leads to higher quality products, better team retention, and the resilience needed to survive the "messy middle" of product development. Key Timestamps00:00 - Introduction of Dr. Jenny Hoffmann and her background in MedTech and innovation. 01:28 - Motivation for writing Open Up: Scaling impact through vulnerable storytelling. 04:23 - The shift from the "perfectly composed" leader to the vulnerable leader. 05:45 - Dr. Hoffmann’s personal origin story: Being one of the first IVF babies in the U.S. 08:30 - Listening to the "whisper" and the courage required to respond to inner intuition. 10:14 - The ROI of Vulnerability: How personal connection drives higher quality and team motivation. 14:39 - Defining SOS moments: Turning distress signals into leadership strengths. 18:42 - The CEC Method: Breaking down Curiosity, Empathy, and Connection. 20:25 - AI in MedTech: Why human empathy is the one thing machines cannot replace. 25:57 - Strategic Sharing vs. Oversharing: How to lead by example without losing professional boundaries. 28:52 - The power of storytelling for engineers and data-driven professionals. Quotes"The leader is the first one to step out on the bridge that no one’s sure if they want to cross. You paint that vision of the bridge, and then you’re the first one to step out on it." - Dr. Hoffman"If we can put empathy first and think about how we are each a patient first... then we can uncover the real needs to solve. Then we can be more innovative." - Dr. HoffmanTakeawaysThe CEC Framework: Use Curiosity to open the mind, Empathy to open the heart, and Connection to drive outsized results in technical teams. Embrace SOS Moments: View professional crises or personal struggles as distress signals that, when analyzed with curiosity, provide the data needed to build resilience. Human-Centric AI Strategy: Leverage AI for efficiency and data processing, but double down on human empathy to solve complex patient needs that machines cannot grasp. Strategic Vulnerability: Sharing personal stories is a leadership skill. Start small by sharing "Monday morning" anecdotes before moving to deeper personal values to build team trust. The Mission Dimension: In MedTech, motivation isn't just about time and effort; it is about the "third dimension" of mission-driven impact that keeps teams moving through the "messy middle" of a project. ReferencesOpen Up: Step Into the Leader You Are Meant to Be by Dr. Jenny Hoffmann – The core book discussed, focusing on vulnerable leadership. New England Medical Innovation Center (NEMIC) – Where Dr. Hoffmann serves as Executive Director. Sure Footing Consulting – Dr. Hoffmann’s leadership and strategy firm. Etienne Nichols LinkedIn – Connect with the host. MedTech 101: SOS MomentsIn a medical context, an SOS is a distress signal indicating an immediate need for help. In leadership, Dr. Hoffmann uses "SOS moments" as an acronym for "Story of Strength" and an analogy for those times when you feel overwhelmed, fearful, or hit a major roadblock in a project (like a failed regulatory submission or a budget crisis), it can also be a moment to look back on and learn from. Just as a clinician responds to a patient’s distress signal by diagnosing the underlying issue, a MedTech leader should respond to their own "emotional SOS" by using the CEC Method. SponsorsThis episode is brought to you by Greenlight Guru. In the medical device industry, the "messy middle" of development is often where teams lose momentum. Greenlight Guru helps you stay focused on your mission by providing the only dedicated MedTech Lifecycle Excellence platform. Their QMS (Quality Management System) ensures your documentation is always audit-ready, while their EDC (Electronic Data Capture) solution streamlines clinical data management. By integrating quality and clinical data, Greenlight Guru allows leaders to spend less time on paperwork and more time on the vulnerable, innovative leadership discussed in today's episode. Feedback Call-to-ActionWe want to hear from you. How do you balance vulnerability with technical authority in your leadership role? Have you experienced an "SOS moment" that changed your career path? Please send your thoughts, reviews, or suggestions for future topics to podcast@greenlight.guru. We read every email and look forward to providing personalized responses to our listeners.

In this episode, Etienne Nichols and guest Ashkon Rasooli explore the transformative impact of AI in the medical device industry. From AI-driven diagnostics and wearable health monitors to the future of surgical robots, they delve into how these technologies are reshaping healthcare. The discussion also touches on the challenges and opportunities in validating and regulating AI within MedTech, highlighting real-world applications and predicting future trends. "Validation of AI tools in MedTech requires a staged adoption to build confidence due to the inherent uncertainty in AI outcomes." - Ashkon Rasooli 00:00 - Introduction to AI in MedTech 05:15 - Discussing AI's deterministic vs. statistical nature 12:30 - AI in diagnostics: Radiology, Cardiology, and Neurology 20:45 - Wearable health monitors and patient-driven health data 28:10 - The role of AI in medical device operations and manufacturing 35:00 - AI at the point of care: Enhancing patient and clinician experience 42:15 - Regulatory challenges and the future of AI in healthcare Key Takeaways: 1. Latest MedTech Trends: The integration of AI in diagnostics is growing, particularly in radiology, cardiology, and neurology, aiding in more accurate and quicker diagnoses. Wearable health monitors are empowering patients to take control of their health data, leading to personalized healthcare solutions. 2. Practical Tips for MedTech Enthusiasts: Stay informed about the latest AI advancements and regulatory guidelines to leverage AI effectively in MedTech. Consider the ethical implications and ensure bias mitigation in AI model training and deployment. 3. Predictions for the Future: Increased adoption of AI across various healthcare sectors, including surgery and patient care management. Evolution of regulatory frameworks to better accommodate and oversee AI-driven medical devices. References: Ashkon Rasooli on LinkedIn ashkon@engeniussolutions.com Engenius Solutions AFDO/RAPS Working Group Etienne Nichols on LinkedIn Sponsors: This episode is brought to you by Greenlight Guru, a comprehensive solution designed to streamline MedTech product development and ensure regulatory compliance. Discover how Greenlight Guru can accelerate your projects at www.greenlight.guru Share your thoughts and questions with us at podcast@greenlight.guru